contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


episurf-scientific-article-on-episealerr-knee-with-up-to-10-years-follow-up-published

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Episurf Medical operates in the medical technology industry and focuses on the development and manufacture of individually adapted implants for joint repair. The company's products are aimed at surgeons and healthcare institutions. The business is global with a main presence in Europe, North America and Asia. Episurf Medical was founded in 2008 and is headquartered in Stockholm, Sweden.

Episurf Medical

Episurf Medical (Nasdaq: EPIS B) today announces that a scientific article including long term clinical results from follow-up of patients who received an Episealer® Knee implant for treatment...

Episurf Medical (Nasdaq: EPIS B) today announces that a scientific article including long term clinical results from follow-up of patients who received an Episealer® Knee implant for treatment of chondral or osteochondral defects in the knee, has been published in Journal of ISAKOS. The publication, with the title "Satisfactory survivorship and clinical outcomes up to 10 years after the implantation of a novel personalized metal implant for the treatment of osteochondral lesions of the knee", by Francesca de Caro et al., presents the clinical outcome and implant survival rate for 34 consecutively recruited patients treated by Prof. Peter Verdonk at AZ Monica, Antwerp, Belgium. The authors conclude that treatment with an Episealer® Knee implant demonstrates encouraging mid-to-long term results with a high survival rate and maintained clinical improvements at up to 10 years' of follow-up. The publication, which is the first Episealer® publication with 10 years' clinical results, shows an implant survival rate of 91,2 % at the latest follow-up, and significant improvement in the patient reported outcome measures KOOS at 2 years, and that the results remained stable at the last follow-up. "This publication highlights how knee cartilage lesions, that can contribute to the development of early osteoarthritis, can be satisfactory treated with the Episealer® Knee implant, and give a sustained clinical outcome. The mean age at surgery was in this study 49.7 years, which shows that the Episealer® Knee works well for the so-called gap patients, that are often considered too old or with too severe damage for biological cartilage repair, while the patients are too young or have too mild damage for full joint replacement. There is a need for treatments that alleviate pain and improve the joint function for this challenging-to-treat group of people, and that is where the Episealer® Knee fits it. We are delighted to see that this study confirms what we have seen so far in other studies, but now over an even longer period of time", says Katarina Flodström, CEO, Episurf Medical. For more information, please contact:Katarina Flodström, CEO, Episurf Medical Tel: +46&nbsp;707 38 35 70 Email: katarina.flodstrom@episurf.comAbout Episurf MedicalEpisurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's&nbsp;μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.The information was submitted for publication, through the agency of the above contact person, at 08:45&nbsp;CEST on October 17, 2025.<div></div>

Episurf: Scientific article on Episealer® Knee with up to 10 years' follow-up published